Zbtb32 ablation worsens CD8 ⁺ T cell anti-tumor capability. (A) Characterization of Zbtb32^−/− mice. (B) Quantification of CD4⁺/CD8⁺ cell ratio in thymus in WT and Zbtb32^−/− mice (n = 6 for each group). (C) Quantification of CD4⁺/CD8⁺ T cell ratio in SPL and LN in WT and Zbtb32^−/− mice (n = 6 for each group). (D) Quantification of different subsets of CD4⁺/CD8⁺ cells in SPL and LN in WT and Zbtb32^−/− mice (n = 6 for each group). (E) Quantification of cell counts of different immune cell types in WT and Zbtb32^−/− CD8⁺ TILs in B16-OVA TME (n = 5 for each group). (F) MFI and quantification of CD44 and Ki-67 in WT and Zbtb32^−/− CD8⁺ TILs in B16-OVA TME (n = 5 for each group). (G) Representative plots and quantification of IFNγ, GzmB, and CD8⁺/CD4⁺ ratio in WT and Zbtb32^−/− CD8⁺ TILs in B16-OVA TME. (H) Representative FACS plots (left panel) and quantification (right panel) of TCF1 and Tim-3 in WT and Zbtb32^−/− CD8⁺ TILs in B16-OVA TME (n = 5 for each group). Data are all shown as means ± SEM; ns, not significant; *P < 0.05 and **P < 0.01 by unpaired two-tailed Student’s t test. Data shown in all graphs are a representative of two independent experiments. Source data are available for this figure: SourceData FS2.